Orion : Distribution of Zoetis products through Orion in Denmark, Norway and Sweden will end after 2020
June 29, 2020 at 10:21 am EDT
Share
Zoetis has announced that the company will establish its own sales and marketing operations in Denmark, Norway and Sweden.
As a result, Orion Veterinary Medicines, part of the Orion Group, will discontinue sales and distribution of Zoetis products in these countries after December 31, 2020.
Zoetis' product portfolio has been part of the sales, marketing and distribution of Orion Veterinary Medicines in Sweden, Norway and Denmark for 20 years. In 2019, sales of the Zoetis product portfolio to Orion in Scandinavia were approximately EUR 25 million. The impact of the product portfolio on the Orion Group's operating profit was not material.
'We would like to thank Zoet for their long and strong cooperation and their contribution to our common success in Scandinavia. Over the years, Orion Veterinary Medicines has developed and built a strong presence in this market. Now we have a unique opportunity to attract new partners, licensable products and new product registrations to take advantage of our strong infrastructure and expertise in the Scandinavian market. We will continue our efforts to grow Orion Veterinary Medicines with new originator medicines that we have in the registration phase in the United States (FDA) and the EU, 'says Niclas Lindstedt , Director of Orion Veterinary Medicines .
Contact:
Niclas Lindstedt
Tel: 050 966 4116
Email: niclas.lindstedt@orion.fi
Orion is a Finnish pharmaceutical company a builder of well-being that operates worldwide. Orion develops, manufactures and markets human and veterinary medicines as well as active pharmaceutical ingredients. The company constantly invests in research and development of new drugs and treatments. The core therapeutic areas of Orion's pharmaceutical research are central nervous system diseases, cancer diseases, rare diseases of the Finnish genetic heritage and respiratory diseases for the treatment of which Orion develops inhaled Easyhaler lung drugs. Orion's net sales in 2019 were EUR 1,051 million, and the company employed about 3,300 people at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
Orion Group Holdings, Inc. is a specialty construction company that serves the infrastructure, industrial, and building sectors. The Company provides services both on and off the water in the continental United States, Alaska, Hawaii, Canada and the Caribbean Basin. It operates through two segments: marine and concrete. The marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. The concrete segment provides turnkey concrete construction services, including place and finish, site prep, layout, forming, and rebar placement for large commercial, structural, and other associated business areas. The Company's specialty services include design, salvage, demolition, surveying, towing, diving and underwater inspection, excavation, and repair.
ORION GROUP HOLDINGS, INC. 
